Judge rejects Allergan challenge to FCA suit
A California judge has allowed a patent attorney to proceed with his claims against Allergan which allege the pharmaceutical company fraudulently obtained patents to monopolise pricing.
AstraZeneca to buy Alexion for $39bn
AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.
Amgen faces struggle to revive cholesterol patents, says Fed Circ judge
Amgen is unlikely to succeed in its bid to revive its patents for the cholesterol drug Repatha, a judge at the US Court of Appeals for the Federal Circuit has told the pharmaceutical company.
90% of essential medicines off-patent, study reveals
Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.
Tris blocks Actavis’ ADHD generic
New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.
Haier division scores win in global patent dispute
Flexicare infringed a breathing tube patent owned by New Zealand appliance maker Fisher & Paykel (F&P), the English High Court has ruled.
Danish university sues Creative Biolabs over ‘antibody pirating’
The University of Southern Denmark has accused biotech Creative Biolabs of infringing its patent-protected monoclonal antibody, HG-HYB 7-5.
Neurim prevails against Mylan in suit over insomnia drug
Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.
Number of pay-for-delay deals remains low, says FTC
The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission.
Illumina, Roche accused of infringing genetic testing patents
Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.
